Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 2Thyroid cancer, medullary 1Renal Insufficiency 1Neoplasms 1Hypertension 1Heart Failure 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

Dexamethasone 7Bortezomib 4Lenalidomide 3pomalidomide 2glucarpidase 2Kidney Transplantation 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1osimertinib 1mirabegron 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Zoledronic Acid 1Urinalysis 1Topotecan 1Thalidomide 1Tablets 1Stents 1Sitagliptin Phosphate 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT01569815 2015-10-19

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Novartis

Phase 1 Completed
32 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡